Journal: Neuropsychopharmacology Reports
Article Title: Distinct Effects of Nonselective Rho‐Kinase Inhibitor Fasudil and Selective Rho‐Kinase 2 Inhibitor KD025 on Serotonin and Dopamine Release in the Nucleus Accumbens of Mice
doi: 10.1002/npr2.70124
Figure Lengend Snippet: Co‐expression of Rho‐kinases 1 and 2 with SERT or DAT. A: Representative immunoreactivity images of Rho‐kinase 1 (green), SERT (magenta), DAT (red), and Hoechst 33342 (blue) in the NAc (scale bar indicates 10 μm). B: Percentage of Rho‐kinase 1 and the SERT or DAT double‐positive area to the SERT or DAT‐positive area in the NAc. C: Representative immunoreactivity images of Rho‐kinase 2 (green), SERT (magenta), DAT (red), and Hoechst 33342 (blue) in the NAc (scale bar indicates 10 μm). D: Percentage of Rho‐kinase 2 and SERT or DAT double‐positive area relative to the SERT or DAT‐positive area in the NAc. Data represent the mean + SEM ( n = 5). DAT, dopamine transporter; SERT, serotonin transporter; NAc, nucleus accumbens.
Article Snippet: The following primary antibodies were used: anti‐Rho‐kinase 1 (Cat#21850–1‐AP, RRID:AB_10953526, 1:100 dilution; Proteintech, IL, USA), anti‐Rho‐kinase 2 (Cat# Ab125025 , RRID:AB_10972853, 1:200 dilution; Abcam, Cambridge, UK), anti‐serotonin transporter (SERT) (Cat#MSFR103270, 1:200 dilution; Nittobo Medical, Tokyo, Japan), and anti‐dopamine transporter (DAT) (Cat#sc‐32258, RRID:AB_627400, 1:250 dilution, Santa Cruz Biotechnology, Texas, USA).
Techniques: Expressing